Author: Chavarria, Adrian Palacios; Lezama, Erika Salinas; Navarro, Mauricio Gonzalez; Vazquez, Rafael Ricardo Valdez; Bello, Héctor Herrera; Gascon, Julieta LomelÃn; Juárez, Linda Morales; Avendaño, Mónica Arboleya; Gonzalez, Luis Esteban Ramirez; Ville Benavides, Rodrigo; Wyssmann, Renate Victoria Ãlvarez; Ortiz, Brenda Sandoval; de la Cerda, Mariana Lizbeth RodrÃguez; Castañeda, Lidia Moreno; Martinez-Juarez, Luis Alberto; Gallardo-Rincón, Héctor; Tapia-Conyer, Roberto
Title: High-flow nasal cannula therapy for hypoxemic respiratory failure in patients with COVID-19 Cord-id: bh166h1e Document date: 2021_9_3
ID: bh166h1e
Snippet: INTRODUCTION: High-flow nasal cannula (HFNC) therapy in patients with hypoxemic respiratory failure due to COVID-19 is poorly understood and remains controversial. METHODS: We evaluated a large cohort of patients with COVID-19-related hypoxemic respiratory failure at the temporary COVID-19 hospital in Mexico City. The primary outcome was the success rate of HFNC to prevent the progression to invasive mechanical ventilation (IMV). We also evaluated the risk factors associated with HFNC success or
Document: INTRODUCTION: High-flow nasal cannula (HFNC) therapy in patients with hypoxemic respiratory failure due to COVID-19 is poorly understood and remains controversial. METHODS: We evaluated a large cohort of patients with COVID-19-related hypoxemic respiratory failure at the temporary COVID-19 hospital in Mexico City. The primary outcome was the success rate of HFNC to prevent the progression to invasive mechanical ventilation (IMV). We also evaluated the risk factors associated with HFNC success or failure. RESULTS: HFNC use effectively prevented IMV in 71.4% of patients [270 of 378 patients; 95% confidence interval (CI) 66.6–75.8%]. Factors that were significantly different at admission included age, the presence of hypertension, and the Charlson comorbidity index. Predictors of therapy failure (adjusted hazard ratio, 95% CI) included the comorbidity-age-lymphocyte count-lactate dehydrogenase (CALL) score at admission (1.27, 1.09–1.47; p < 0.01), Rox index at 1 hour (0.82, 0.7–0.96; p = 0.02), and no prior steroid treatment (0.34, 95% CI 0.19–0.62; p < 0.0001). Patients with HFNC success rarely required admission to the intensive care unit and had shorter lengths of hospital stay [19/270 (7.0%) and 15.0 (interquartile range, 11–20) days, respectively] than those who required IMV [104/108 (96.3%) and 26.5 (20–36) days, respectively]. CONCLUSION: Treating patients with HFNC at admission led to improvement in respiratory parameters in many patients with COVID-19.
Search related documents:
Co phrase search for related documents- absolute lymphocyte count and admission day: 1, 2, 3
- absolute lymphocyte count and admission score: 1, 2, 3
- absolute lymphocyte count and low resource: 1
- absolute lymphocyte count and low resource setting: 1
- absolute lymphocyte count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute respiratory distress and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute respiratory distress and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory distress and admission score: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
- acute respiratory distress and admission significant difference: 1, 2, 3
- acute respiratory distress and low oxygen saturation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory distress and low resource: 1, 2, 3, 4, 5, 6, 7
- acute respiratory distress and low resource setting: 1
- acute respiratory distress and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65
- acute respiratory distress patient and admission day: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory distress patient and admission score: 1
- acute respiratory failure and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
- acute respiratory failure and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory failure and admission score: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute respiratory failure and admission significant difference: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date